Compare Stocks: AGRX, KPTI, ATHE, and CRVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGRX Agile Therapeutics	$1.51	$1.49	$0.20 ▼ $2.63	$10.35M	1.58	352,864 shs	N/A
ATHE Alterity Therapeutics	$4.54 +0.4%	$4.81	$2.66 ▼ $5.89	$82.29M	0.27	17,766 shs	4,562 shs
CRVO CervoMed	$2.56 +0.8%	$2.90	$2.13 ▼ $10.74	$38.71M	-0.64	303,968 shs	108,415 shs
KPTI Karyopharm Therapeutics	$1.79 +1.1%	$5.27	$1.72 ▼ $10.99	$40.15M	0.95	1.27 million shs	577,293 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGRX Agile Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ATHE Alterity Therapeutics	+0.44%	+0.67%	+3.89%	+16.41%	-10.45%
CRVO CervoMed	+0.79%	-1.54%	-8.90%	-12.93%	-76.05%
KPTI Karyopharm Therapeutics	+1.13%	-4.28%	-6.28%	-80.29%	-74.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGRX Agile Therapeutics	$1.51	$1.49	$0.20 ▼ $2.63	$10.35M	1.58	352,864 shs	N/A
ATHE Alterity Therapeutics	$4.54 +0.4%	$4.81	$2.66 ▼ $5.89	$82.29M	0.27	17,766 shs	4,562 shs
CRVO CervoMed	$2.56 +0.8%	$2.90	$2.13 ▼ $10.74	$38.71M	-0.64	303,968 shs	108,415 shs
KPTI Karyopharm Therapeutics	$1.79 +1.1%	$5.27	$1.72 ▼ $10.99	$40.15M	0.95	1.27 million shs	577,293 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGRX Agile Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ATHE Alterity Therapeutics	+0.44%	+0.67%	+3.89%	+16.41%	-10.45%
CRVO CervoMed	+0.79%	-1.54%	-8.90%	-12.93%	-76.05%
KPTI Karyopharm Therapeutics	+1.13%	-4.28%	-6.28%	-80.29%	-74.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGRX Agile Therapeutics	0.00	N/A	N/A	N/A
ATHE Alterity Therapeutics	2.50	Moderate Buy	$10.00	120.26% Upside
CRVO CervoMed	2.71	Moderate Buy	$21.00	720.31% Upside
KPTI Karyopharm Therapeutics	2.57	Moderate Buy	$11.50	542.46% Upside

Current Analyst Ratings Breakdown

Latest AGRX, KPTI, ATHE, and CRVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/13/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	ATHE Alterity Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/3/2026	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGRX Agile Therapeutics	$19.98M	0.52	N/A	N/A	($5.51) per share	-0.27
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$3.27 per share	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	$1.52 per share	N/A
KPTI Karyopharm Therapeutics	$146.07M	0.28	N/A	N/A	($14.56) per share	-0.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGRX Agile Therapeutics	-$14.47M	-$3.65	N/A	N/A	N/A	-36.24%	N/A	-147.37%	N/A
ATHE Alterity Therapeutics	-$15.89M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	-$26.97M	-$3.22	N/A	N/A	N/A	-672.80%	-156.02%	-128.34%	11/12/2026 (Estimated)
KPTI Karyopharm Therapeutics	-$196.04M	-$13.09	N/A	N/A	N/A	-153.28%	N/A	-145.18%	11/2/2026 (Estimated)

Latest AGRX, KPTI, ATHE, and CRVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	KPTI Karyopharm Therapeutics	-$1.37	-$2.32	-$0.95	-$2.32	$32.19 million	$33.43 million
8/7/2026	Q2 2026	CRVO CervoMed	-$0.8640	-$0.64	+$0.2240	-$0.64	$0.05 million	N/A
7/30/2026	Q4 2026 TU	ATHE Alterity Therapeutics	N/A	-$0.28	N/A	-$0.28	N/A	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGRX Agile Therapeutics	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGRX Agile Therapeutics	N/A	0.56	0.38
ATHE Alterity Therapeutics	N/A	14.52	N/A
CRVO CervoMed	N/A	8.57	8.57
KPTI Karyopharm Therapeutics	N/A	0.79	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGRX Agile Therapeutics	10.92%
ATHE Alterity Therapeutics	2.14%
CRVO CervoMed	25.15%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
AGRX Agile Therapeutics	0.50%
ATHE Alterity Therapeutics	38.80%
CRVO CervoMed	35.80%
KPTI Karyopharm Therapeutics	1.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGRX Agile Therapeutics	30	6.86 million	6.82 million	Not Optionable
ATHE Alterity Therapeutics	10	18.13 million	5.43 million	Not Optionable
CRVO CervoMed	4	15.12 million	9.71 million	Not Optionable
KPTI Karyopharm Therapeutics	380	22.68 million	22.30 million	Optionable

AGRX, KPTI, ATHE, and CRVO Headlines

Recent News About These Companies

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from Analysts

September 5 at 2:58 AM | americanbankingnews.com

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

September 4 at 8:28 AM | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)

September 3 at 7:24 AM | theglobeandmail.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | prnewswire.com

Karyopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

August 31, 2026 | finanznachrichten.de

Karyopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib

August 31, 2026 | rttnews.com

Karyopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock Up

August 31, 2026 | rttnews.com

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

August 31, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 27, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 25, 2026 | globenewswire.com

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving Average - Time to Sell?

August 25, 2026 | americanbankingnews.com

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

August 21, 2026 | finance.yahoo.com

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 20, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 18, 2026 | globenewswire.com

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

August 13, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

August 13, 2026 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2026 | zacks.com

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

August 13, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AGRX, KPTI, ATHE, and CRVO Company Descriptions

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Alterity Therapeutics NASDAQ:ATHE

$4.54 +0.02 (+0.44%)

As of 09/4/2026 04:00 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

CervoMed NASDAQ:CRVO

$2.56 +0.02 (+0.79%)

As of 09/4/2026 04:00 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$1.79 +0.02 (+1.13%)

As of 09/4/2026 04:00 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGRX, KPTI, ATHE, and CRVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGRX, KPTI, ATHE, and CRVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGRX, KPTI, ATHE, and CRVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGRX, KPTI, ATHE, and CRVO Company Descriptions

Agile Therapeutics NASDAQ:AGRX

Alterity Therapeutics NASDAQ:ATHE

CervoMed NASDAQ:CRVO

Karyopharm Therapeutics NASDAQ:KPTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGRX, KPTI, ATHE, and CRVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGRX, KPTI, ATHE, and CRVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGRX, KPTI, ATHE, and CRVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGRX, KPTI, ATHE, and CRVO Company Descriptions

Agile Therapeutics NASDAQ:AGRX

Alterity Therapeutics NASDAQ:ATHE

CervoMed NASDAQ:CRVO

Karyopharm Therapeutics NASDAQ:KPTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools